Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.

scientific article

Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/AJH.23546
P698PubMed publication ID23861234

P50authorGianpietro SemenzatoQ42574068
Livio TrentinQ56383785
Francesco ZajaQ57307002
Renato FaniQ61307102
Francesco RodeghieroQ87875711
Rossella PaoliniQ89761693
Miriam IsolaQ102150006
P2093author name stringCarlo Visco
Stefano Volpetti
Achille Ambrosetti
Michael Mian
Giovanni Pizzolo
Sergio Cortelazzo
Paolo Vivaldi
Rosaria Sancetta
Ilaria Nichele
Monica Castelli
Simona Puglisi
Cinzia Sissa
P2860cites workGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesQ24616084
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-upQ27851444
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemiaQ27851685
Genomic aberrations and survival in chronic lymphocytic leukemiaQ28141442
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemiaQ28394721
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractorinessQ29013141
Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphomaQ33366403
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemiaQ33377308
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphomaQ33380352
ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patientsQ33390369
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupQ33396737
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupQ33402713
The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemiaQ33406164
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trialQ34141305
The clinical and epidemiological burden of chronic lymphocytic leukaemiaQ35804467
Treatment of elderly patients with chronic lymphocytic leukemiaQ37386705
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaQ37634897
Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell linesQ39359493
Bendamustine-associated hemolytic anemiaQ43266151
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.Q52621343
P433issue11
P921main subjectbendamustineQ425745
lymphocyteQ715347
chronic lymphocytic leukemiaQ1088156
P304page(s)955-960
P577publication date2013-09-09
P1433published inAmerican Journal of HematologyQ4744246
P1476titleBendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice
P478volume88

Reverse relations

cites work (P2860)
Q35483796A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency
Q38676858Bendamustine associated immune suppression and infections during therapy of hematological malignancies
Q38979354Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials
Q41257177Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study
Q31056968Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Q21198858Novel agents for chronic lymphocytic leukemia
Q24186840Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis
Q39180275The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia

Search more.